RT Journal Article
SR Electronic
T1 Cervical Cancer Screening Using Residual Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.19.22283665
DO 10.1101/2022.12.19.22283665
A1 Abdulsamad, Mohamed
A1 Alshareef, Esam Alsadiq
A1 Ebrahim, Fawzi
YR 2022
UL http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283665.abstract
AB Cervical cancer is a leading cancer in the female population. This disease is considered dangerous as its slow and unpredicted growth. The prevention of such cancer can be mostly achieved by screening its transformation zones. The cervical pre-cancerous zones can be considered as three types: type 1, type 2, and type 3. Screening and analyzing these three stages can be crucial for preventing their transformation into cancer. Hence, it is essentially important to have an automated and intelligent system that can grade the cervical pre-cancerous colposcopy images into one of the three types. This can help in providing the right treatment and prevent cancer transformation. In this paper, we develop a residual learning-based model (ResNet-50) to be trained for classifying the type of a colposcopy cervical image into type 1, type 2, and type 3. Experimentally, the model was fine-tuned and evaluated on a public dataset of colposcopy cervical images and achieved promising results in cervical cancer screening of accuracy of 77% and F1-score of 79%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.kaggle.com/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.